Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=program_officials" }, "data": [ { "type": "Grant", "id": "15730", "attributes": { "award_id": "2515959", "title": "Determining how the evolution of the coronavirus macrodomain contributes to its biochemical and virological functions", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Biological Sciences (BIO)", "Genetic Mechanisms" ], "program_reference_codes": [], "program_officials": [ { "id": 32783, "first_name": "Diana", "last_name": "Chu", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": null, "award_amount": 1000000, "principal_investigator": { "id": 32785, "first_name": "Anthony", "last_name": "Fehr", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32784, "first_name": "Robert L", "last_name": "Unckless", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 415, "ror": "", "name": "University of Kansas Center for Research Inc", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true }, "abstract": "This project explores how macrodomain proteins have evolved to balance their different multiple biochemical activities. Macrodomains are ancient enzymes that bind to and remove ADP-ribose, an important post-translation modification that is critical in several cellular stress responses, including DNA damage, ER stress, and virus infection. These enzymes are conserved through all domains of life, including archaea, bacteria, eukaryotes, and viruses, indicating that they are critical for multiple cellular processes. However, the function of macrodomain enzymes in cell biology and microbiology are just now being uncovered. Furthermore, recent research indicates that macrodomains have evolved to properly balance their biochemical functions depending on if they are expressed from a virus, a bacteria, or from a eukaryotic cell. This project will evaluate how viral macrodomains have evolved to develop the ideal biochemical properties that allow them function in the context of a virus infection. This project also has strong educational and community outreach components. Most notably, students at all training levels will participate in this project and will learn how to evaluate the evolution of proteins through workshops in phylogenetics. This project will provide new insights into the fundamental biology of macrodomain enzymes and could lead to new insights into antiviral drug-development. This project aims to define how the coronavirus macrodomain has evolved to best function in the context of a virus infection using the mouse coronavirus, murine hepatitis virus (MHV), as a model. The use of MHV, which is unable to infect humans, for creating macrodomain mutations eliminates the potential for gain-of-function research. Research over the last decade has demonstrated that the coronavirus macrodomain blocks innate immune responses, is critical for viral pathogenesis, and is a potential drug target. Furthermore, the macrodomain uses both its ADP-ribose binding and hydrolysis activities to promote virus replication, and they must be balanced for optimal replication. The PI will use recombinant proteins and a panel of recombinant viruses, developed using a bacterial artificial chromosome based reverse genetic system, to better understand how highly conserved amino acids and selective pressure induced mutations impact Mac1 biochemical activities, virus replication, and pathogenesis using well-established assays and model systems. Additionally, macrodomains from across the evolutionary spectrum will be expressed in the context of MHV infection to define the evolutionary limits of macrodomain divergence that is tolerated in MHV. This work will provide a deeper understanding of how macrodomains have evolved to counter various ADP-ribose dependent antiviral responses. This project is jointly funded by the Genetic Mechanisms Program and the Division of Molecular and Cellular Biosciences. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15731", "attributes": { "award_id": "2449818", "title": "Collaborative Research: CUE-T: Broadening Participation in Computing via Active Learning Strategies in Multi-Institution Online Synchronous Learning Environments", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "IUSE" ], "program_reference_codes": [], "program_officials": [ { "id": 32786, "first_name": "Stephanie", "last_name": "Gage", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": null, "award_amount": 219994, "principal_investigator": { "id": 27263, "first_name": "Vijayalakshmi", "last_name": "Ramasamy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 956, "ror": "", "name": "Georgia Southern University Research and Service Foundation, Inc", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Due to the COVID pandemic, most U.S. Institutions of Higher Education (IHEs) transitioned in-person classes to online classes. Such a transition provides fertile ground for research into improving undergraduate STEM education in computing fields, specifically in broadening participation for underrepresented students and improving learning outcomes. There are ongoing challenges in attracting and retaining students to computing. This project intends to explore the impact of combining effective active learning approaches in computing courses in online synchronous learning environments (OSLEs) across multiple institutions with a Learning Assistant model. The proposed approach has the potential to improve student learning outcomes and retention rates in computing. This project's primary goal is to explore the impact of integrating effective active learning approaches in computing OSLEs and sharing resources across multiple institutions on students' learning outcomes, engagement, and retention. The project team plans to use a mixed-methods experimental design to investigate four research questions focusing on conducting professional development, using active learning approaches on student learning outcomes and retention rates, and sharing courses across institutions. This project will be conducted at six institutions, including two Hispanic Serving Institutions, two Historically Black Universities, and two small universities. This proposed project has the potential to significantly pathways for computing in both academia and industry. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15732", "attributes": { "award_id": "2424180", "title": "S-STEM: Bothell Engineering and Technology Scholars", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "S-STEM-Schlr Sci Tech Eng&Math" ], "program_reference_codes": [], "program_officials": [ { "id": 32787, "first_name": "Gordon", "last_name": "Uno", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": null, "award_amount": 1999995, "principal_investigator": { "id": 32790, "first_name": "Cinnamon", "last_name": "Hillyard", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 8271, "first_name": "Jennifer", "last_name": "McLoud-Mann", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32788, "first_name": "Tadesse", "last_name": "Ghirmai", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32789, "first_name": "Yusuf", "last_name": "Pisan", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The UW Bothell Engineering and Technology Scholars project will contribute to the national need for well-educated scientists, mathematicians, engineers, and technicians by supporting the retention and graduation of high-achieving, low-income students with demonstrated financial need at the University of Washington Bothell. UW Bothell is a Minority Serving Institution, and its student body is one of the most diverse in the state where 38% of incoming first-year students are first generation and 28% are eligible for federal Pell Grants. Over its six-year duration, this Track 2 S-STEM project will fund scholarships to 60 unique full-time students who are pursuing bachelor's degrees in Engineering and Technology (E&T), including computer and software systems, computer engineering, mechanical engineering, electrical engineering, data visualization, mathematics, and physics. Project activities include dedicated math and science courses and cohort-based programming that provides academic success workshops, networking and career development opportunities, and faculty mentoring. Faculty mentors will learn about proven best practices and support each other through a faculty learning community. This project investigates which of several evidence-based strategies are the most effective in supporting and training low-income students specifically interested in E&T degrees through their journey from first year through graduation. In addition to measuring traditional elements of student success such as pass, persistence, and graduation rates, the project tracks students' sense of purpose, academic and social belonging, career readiness, and overall well-being. Faculty will deepen their understanding of the complex student experiences and use this knowledge to help address institutional barriers for all students entering UW Bothell in the post-pandemic era. The overall goal of this project is to increase STEM degree completion of academically talented, low-income undergraduates with demonstrated financial need. This project seeks to increase the percentage of students who complete an E&T major by providing coaching, dedicated academic support, and re-designed prerequisite courses; increase the number of students obtaining an E&T major by providing faculty mentoring, networking, and career development opportunities that promote a sense of belonging and a sense of purpose; and enhance faculty and staff ability to best support student populations by creating an ongoing faculty learning community. Currently, only 30% of incoming students who want to pursue E&T degrees graduate with an E&T degree, and the diversity of the incoming class is starkly different from the graduating class. National and institutional research indicates that the loss of UW Bothell students in E&T fields can be attributed to four primary barriers: financial burdens, early academic struggles, a lack of sense of belonging and purpose, and complex institutional systems. Research has shown that providing financial support, academic support through dedicated coursework and academic seminars, mentoring, cohort experiences, and/or career development opportunities can help bridge these barriers. The project will provide additional support to faculty mentors to help students overcome these barriers and provide faculty opportunities to learn about and address institutional barriers. Most research studies only examine one or two of these components. This project seeks to understand which combination of programing, academic support, pedagogical approaches, and faculty mentoring have the greatest impact for low-income students by implementing an extensive assessment plan. The assessment plan utilizes both formative and summative evaluation methods that include student and faculty mentor surveys, student focus groups, and monitoring of institutional data to explore our research questions: (1) How are academic supports affecting students' academic skills and metrics of success? (2) How are mentorship and professional development activities affecting students' sense of belonging, purpose, and commitment to pursuing a STEM degree? (3) What is the relative importance of various program elements for retaining students in STEM? (4) How is the faculty mentor learning community affecting faculty perceptions of student experience and assets? (5) To what extent is the program providing responsive program supports and how can the program supports be improved? Results of the project will be published in journal articles and presented at conferences. Project information will also be available on a public website. This project is funded by NSF's Scholarships in Science, Technology, Engineering, and Mathematics program, which seeks to increase the number of low-income academically talented students with demonstrated financial need who earn degrees in STEM fields. It also aims to improve the education of future STEM workers, and to generate knowledge about academic success, retention, transfer, graduation, and academic/career pathways of low-income students. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15742", "attributes": { "award_id": "1R21AI188400-01A1", "title": "Uncovering mechanisms that underpin bat virus virulence", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32795, "first_name": "EUN-CHUNG", "last_name": "PARK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-04", "end_date": "2027-07-31", "award_amount": 455692, "principal_investigator": { "id": 26531, "first_name": "Cara", "last_name": "Brook", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2613, "ror": "", "name": "UNIVERSITY OF CALIFORNIA BERKELEY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Bats are reservoir hosts for zoonoses that cause the highest case fatality rates documented in humans, including rabies and related lyssaviruses, Hendra and Nipah henipaviruses, Ebola and Marburg filoviruses, and SARS and MERS coronaviruses. Bats exhibit limited disease upon infection with these viruses that cause extreme pathology in other mammals, likely due to robust and rapid innate and cell-mediated immune defenses, coupled with hyper-efficient mechanisms of DNA damage repair and dampened inflammatory pathways. Recent theoretical work in our lab demonstrates how these unique features of bat immunology and physiology—chiefly, constitutive antiviral immunity and resilience to inflammation that confers tolerance to immunopathology—should select for the evolution of high virus growth rates that, while avirulent to bats, are likely to cause pathology following spillover to non-bat, including human, hosts. Here, we seek to explicitly test the predictions of our theoretical model by carrying out experimental evolution of vesicular stomatitis virus (VSV) in bat cell cultures that span a range of both (Aim 1) constitutive antiviral and (Aim 2) inflammation tolerant phenotypes. Under Aim 1, we examine variation in VSV growth rate evolution and the rate of molecular evolution following serial passage of virus across a suite of Pteropus alecto bat cell lines that exhibit both intact (wildtype) and deficient (CRISPR knock-outs) antiviral immune functions. Under Aim 2, we leverage our lab’s unique system of primary bat fibroblast cell lines derived from related species spanning a range of longevities to evaluate whether cells derived from longer-lived species that demonstrate resilience to aging-related stressors also exhibit heightened tolerance of virus infection. We then compare VSV evolution following serial passage across cell lines that demonstrate variable resilience to aging-related stressors in vitro. We hypothesize that antiinflammatory properties in bat cells which confer resilience to aging stressors may also facilitate virus tolerance by limiting immunopathology and—by extension—drive the evolution of high growth rate viruses likely to generate pathology in non-bat hosts. Ultimately, we offer an explicit empirical test of the hypothesized mechanisms underpinning the extreme virulence of bat virus zoonoses.", "keywords": [ "Acceleration", "Aging", "Anti-Inflammatory Agents", "Anti-viral Response", "Automobile Driving", "Birds", "Body Size", "Case Fatality Rates", "Cell Culture Techniques", "Cell Line", "Cells", "Chiroptera", "Clustered Regularly Interspaced Short Palindromic Repeats", "Coupled", "DNA Repair", "Data", "Disease", "Ebola", "Evolution", "Exhibits", "Fibroblasts", "Filovirus", "Genes", "Genome", "Genus Pteropus", "Growth", "Harvest", "Hendra Virus", "Human", "IFNAR2 gene", "IRF1 gene", "IRF3 gene", "Immune", "Immune response", "Immunity", "Immunologics", "Immunology", "In Vitro", "Indiana", "Infection", "Inflammation", "Inflammatory", "Interferons", "Knock-out", "Link", "Literature", "Locomotion", "Longevity", "Lyssavirus", "Mammals", "Marburgvirus", "Mediating", "Metabolic", "Metabolic stress", "Middle East Respiratory Syndrome Coronavirus", "Molecular", "Molecular Evolution", "Nipah Virus", "Paper", "Pathology", "Pathway interactions", "Phenotype", "Physiological", "Physiology", "Plaque Assay", "Process", "Property", "Public Health", "RNA", "Rabies", "Regulator Genes", "Research", "Residual state", "Resistance", "SARS coronavirus", "Secondary to", "Serial Passage", "Serotyping", "Signal Transduction", "System", "Testing", "Theoretical model", "Variant", "Vesicular stomatitis Indiana virus", "Viral", "Viral Load result", "Virulence", "Virulent", "Virus", "Virus Diseases", "Work", "Zoonoses", "aging related", "anti aging", "antiviral immunity", "burden of illness", "cellular resilience", "comparative", "cost", "experience", "experimental study", "extend lifespan", "immune function", "immunopathology", "life span", "oxidative damage", "predictive modeling", "rapid growth", "resilience", "resilience in aging", "response", "stressor", "theories", "trait", "transcriptome sequencing", "transcriptomics", "transmission process", "viral resistance" ], "approved": true } }, { "type": "Grant", "id": "15743", "attributes": { "award_id": "1R34HL173375-01A1", "title": "Democratizing Access to Cleaner Residential Air (DACRA)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32796, "first_name": "MICHELLE M", "last_name": "FREEMER", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-15", "end_date": "2028-07-31", "award_amount": 293395, "principal_investigator": { "id": 32797, "first_name": "Doug", "last_name": "Brugge", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2614, "ror": "", "name": "UNIVERSITY OF CONNECTICUT SCH OF MED/DNT", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Particulate air pollution (PM2.5) is the 4th leading cause of morbidity and mortality. Attention from leading health organizations has recently turned to interventions to reduce exposure and prevent adverse health outcomes. As evidence has begun to mount for the efficacy of these machines, and will likely grow further in the coming years, it has, however, become apparent that for most people, including low-income populations in the US, cannot afford effective commercially available units. Low-cost commercial air purifiers are of low efficacy and often introduce new pollutants into the air. To our knowledge, there are no published intervention studies of Corsi-Rosenthal Boxes (C-R Boxes), the devices we propose to use in this study. We have a study team that is ideally suited for the proposed research. Ms. Creed has extensive experience building and deploying the C-R Boxes which became popular during the Covid pandemic. Dr. Brugge has three published RCTs of high-quality commercial air purifiers and another, full trial, nearing completion. Thus, he has knowledge and experience which qualifies him to lead this proposed study. Drs. Levy Zamora has extensive air monitoring expertise, will direct measurement of indoor and outdoor air pollution concentrations at each home. Dr. Eliasziw is a biostatistician with extensive experience analyzing randomized trials. We have three aims: 1)Conduct focus groups/interviews and BP measurements with participants who meet study inclusion criteria to refine our protocol; 2) Conduct a randomized crossover pilot trial with 65 participants to calculate preliminary effect size estimates to inform a larger crossover efficacy trial; and 3) Determine the feasibility of conducting a larger crossover efficacy multisite trial in the US. We will conduct our randomized cross over trial in three settings with low, medium, and high air pollution. Our low and medium air pollution locations will be in Hartford CT and our high pollution setting will be in Boston Chinatown, where we can reliably expect high pollution levels. Participants (N=65) will have dried blood spots collected and blood pressure measured at the start and end of each 4-week intervention session. Our randomized cross over design controls for time invariant confounding. Interviews and standardized questionnaires with study participants will provide feedback that will inform the decision as to whether to proceed with a full trial. We seek to meet targets for 80% recruitment and retention as well as 80% satisfaction as benchmarks for moving to a full trial. The findings for health end points will provide preliminary data to justify the potential future R01 proposal for a fully powered clinical trial. An expert elicitation process conducted with the research team in the final year will make the final decision about a future, full trial. The significance of this work is that showing efficacy of C-R Boxes for reducing exposure would lead to their widespread use and contribute to improving public health", "keywords": [ "Africa", "Air", "Air Movements", "Air Pollutants", "Air Pollution", "Allergens", "American Heart Association", "Asia", "Attention", "Benchmarking", "Biological Markers", "Blood", "Blood Glucose", "Blood Pressure", "Boston", "COVID-19 pandemic", "Cardiopulmonary", "Cardiovascular Diseases", "Cardiovascular system", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Childhood Asthma", "Clinical Trials", "Consensus", "Country", "Cross-Over Trials", "Crossover Design", "Data", "Developed Countries", "Devices", "Diet", "Dryness", "Educational workshop", "Exposure to", "Fasting", "Feedback", "Filtration", "Focus Groups", "Future", "Goals", "Health", "Health Benefit", "Home", "Hour", "Household", "Income", "Indoor Air Pollution", "Inflammation", "Interleukin-6", "Intervention", "Intervention Studies", "Interview", "Knowledge", "Lead", "Link", "Location", "Low Income Population", "Measurement", "Measures", "Meta-Analysis", "Morbidity - disease rate", "Outcome", "Participant", "Particulate", "Particulate Matter", "Persons", "Pollution", "Power Sources", "Predisposition", "Process", "Protocols documentation", "Public Health", "Publishing", "Qualifying", "Questionnaires", "Randomized", "Research", "Risk", "Sampling", "Spottings", "Standardization", "Time", "Tobacco", "Translating", "United States Environmental Protection Agency", "United States National Institutes of Health", "Vulnerable Populations", "Whole Blood", "Work", "acceptability and feasibility", "air filter", "air monitoring", "ambient air pollution", "cost", "efficacy trial", "epidemiology study", "experience", "feasibility testing", "feasibility trial", "fine particles", "health assessment", "health organization", "health related quality of life", "high risk population", "improved", "inclusion criteria", "indoor concentrations", "inflammatory marker", "innovation", "meter", "mortality", "multi-site trial", "noise perception", "particle", "peripheral blood", "pilot trial", "pollutant", "portability", "prevent", "randomized trial", "randomized clinical trials", "recruit", "respiratory", "satisfaction", "systematic review", "systemic inflammatory response" ], "approved": true } }, { "type": "Grant", "id": "15744", "attributes": { "award_id": "1U19AI189183-01", "title": "Accelerator for the rapid development of countermeasures targeting drug resistant fungal pathogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32798, "first_name": "PING", "last_name": "CHEN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-06-30", "award_amount": 6977446, "principal_investigator": { "id": 8841, "first_name": "Arturo", "last_name": "Casadevall", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23143, "first_name": "David S", "last_name": "Perlin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1487, "ror": "https://ror.org/008zj0x80", "name": "Hackensack University Medical Center", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 2615, "ror": "", "name": "JOHNS HOPKINS UNIVERSITY", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Invasive fungal infections pose a significant medical challenge, particularly for individuals with compromised immune systems or other conditions due to HIV, cancer, organ transplantation, diabetes, chronic respiratory ailments, tuberculosis, COVID-19, and influenza. Prompt diagnosis and effective antifungal treatment are crucial for positive clinical outcomes. Current antifungal drugs are limited in number and efficacy, and their effectiveness has been compromised by the emergence of drug-resistant strains, notably Candida auris, Candida glabrata, and Aspergillus fumigatus. To combat this growing problem, there is an urgent need to develop new drugs capable of effectively treating invasive infections caused by drug-resistant fungal pathogens. Additionally, actionable point-of-care diagnostics for Candida bloodstream infections are essential for initiating timely and appropriate therapy, ultimately reducing overall mortality rates. While efforts from the biopharmaceutical industry have led to some expansion in the antifungal pipeline, more potent and targeted drugs are urgently required. In response to these pressing challenges, a Center of Excellence in Translational Research (CETR) focused on rapid drug and diagnostic development will be established. This Center harnesses expertise of leading academic and industry professionals, many of whom have a track record of successfully bringing FDA-approved products to market. The Projects selected encompass a wide range of new and established pharmacological drug targets, as well as a state-of-the-art diagnostic platform. Among the projects underway, collaborations with biopharmaceutical partners Prokaryotics and Scynexis are focused on the development of advanced small molecules targeting key enzymes involved in cell wall biogenesis. Additionally, efforts are underway to develop an antibody-based immunotherapy to combat drug-resistant infections. Finally, a Project dedicated to creating a novel point-of-care diagnostic capable of rapidly detecting Candida bloodstream infections in partnership with Cepheid Diagnostics on the GeneXpert platform, holds promise for revolutionizing the diagnosis and management of fungal infections. An integrated network of science cores staffed by experienced directors, facilitate efficient compound optimization and progression through clear ‘go, no-go’ metrics. While all programs prioritize high-threat drug-resistant Candida species, some drug candidates may also demonstrate efficacy against azole-resistant Aspergillus fumigatus. In summary, this CETR-based drug and diagnostic development accelerator represents a concerted effort to address the pressing need for novel treatments and diagnostics for invasive fungal infections. By leveraging the expertise of industry and world class translational academic partners, this initiative aims to rapidly advance innovative solutions to combat antifungal drug resistance and improve clinical outcomes for patients affected by these challenging fungal infections. The anticipated outcome of our successful efforts will be to create two IND-ready small molecule drug candidates, a lead optimized novel immunotherapy, and a 510(k) ready point-of-care diagnostic for bloodstream infections.", "keywords": [ "Academia", "Acceleration", "Address", "Advanced Development", "Affect", "Animal Model", "Antibodies", "Aspergillus fumigatus", "Azole resistance", "Biogenesis", "Biological Products", "Blood", "COVID-19", "Candida", "Candida auris", "Candida glabrata", "Cell Wall", "Chronic", "Clinical", "Collaborations", "Death Rate", "Dedications", "Detection", "Development", "Diabetes Mellitus", "Diagnosis", "Diagnostic", "Disease", "Drug Targeting", "Drug resistance", "Effectiveness", "Ensure", "Enzymes", "FDA approved", "Fungal Drug Resistance", "GPI Membrane Anchors", "Goals", "HIV", "Immune system", "Immunocompromised Host", "Immunotherapy", "Individual", "Industry", "Infection", "Influenza", "Investigational Drugs", "Knowledge", "Lead", "Life", "Malignant Neoplasms", "Marketing", "Medical", "Microbiology", "Mission", "Mycoses", "Organ Transplantation", "Outcome", "Patient-Focused Outcomes", "Pharmaceutical Chemistry", "Pharmaceutical Preparations", "Pharmacology", "Pharmacotherapy", "Process", "Productivity", "Public Health", "Rapid diagnostics", "Records", "Resistance", "Resistant candida", "Resources", "Respiration Disorders", "Science", "Standardization", "The science of Mycology", "Therapeutic", "Time", "Translational Research", "Transplantation", "Tuberculosis", "anti-fungal agents", "biopharmaceutical industry", "bloodstream infection", "combat", "diagnostic development", "diagnostic platform", "diagnostic tool", "diagnostic value", "drug candidate", "drug development", "experience", "formulation optimization", "glucan synthase", "improved", "in vivo", "in vivo Model", "innovation", "lead optimization", "mannoproteins", "mortality", "novel", "novel therapeutics", "pathogen", "pathogenic fungus", "pharmacologic", "point of care", "point-of-care diagnostics", "preclinical development", "prevent", "programs", "rapid detection", "resistant Aspergillus", "resistant strain", "respiratory", "response", "small molecule" ], "approved": true } }, { "type": "Grant", "id": "15746", "attributes": { "award_id": "1R21AI188180-01A1", "title": "Determining the role of PARP14 in restricting HSV-1 replication", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32800, "first_name": "LESLEY CONRAD", "last_name": "DUPUY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2027-07-31", "award_amount": 411499, "principal_investigator": { "id": 32801, "first_name": "David J", "last_name": "Davido", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 24962, "first_name": "Anthony R", "last_name": "Fehr", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1496, "ror": "", "name": "UNIVERSITY OF KANSAS LAWRENCE", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 2617, "ror": "", "name": "UNIVERSITY OF KANSAS LAWRENCE", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true }, "abstract": "Herpes simplex virus 1 (HSV-1) infects 70-90% of the human population and causes significant diseases such as blindness and life-threatening encephalitis, most notably in immunocompromised individuals. In contrast, most infections of immunocompetent hosts are asymptomatic and result in viral latency. Limited disease in most human hosts is likely the result of millions of years of co-evolution between HSV-1 and humans, due, in part, to a wide variety of host restriction factors that limit early stages of HSV-1 replication. Understanding the mechanisms used by humans to repress HSV-1 replication will help identify treatments that can mitigate severe HSV-1 diseases, especially in immunocompromised hosts. In a screen designed to identify novel host proteins that interact with the HSV-1 genome, 3 poly(ADP-ribose) polymerase (PARP) proteins were identified that bound to HSV-1 DNA with high confidence: PARP1, PARP9, and PARP14. Interestingly, prior studies had also found that these three PARP proteins were bound to HSV-1 genomic DNA, providing strong evidence that these PARP proteins could impact the replication of HSV-1, even though there have been very few reports of PARPs associated with HSV-1 replication. In addition, PARP14 has been evolving under positive selection, suggesting that it is involved in host-virus conflict, and we recently demonstrated that it can restrict coronavirus replication. Thus, the ability of HSV-1 to replicate in PARP14 knockout (KO) A549 cells was tested, and surprisingly PARP14 KO cells produced 1-2 logs more in viral yield assays and increased the plaquing efficiency ~2-logs higher compared to WT A549 cells. These results support the central hypothesis that PARP14 binds to the HSV-1 genome early in infection, leading to significant repression of HSV-1 replication. The overall objective of this application is to establish PARP14 as a novel host restriction factor and determine how it binds to the viral genome and inhibits virus replication. These objectives will be achieved through the following specific aims: 1) Establish PARP14 as a potent restriction factor for HSV-1 in cell culture and in mice; and 2) Determine how PARP14 represses the HSV-1 replication cycle and define how it binds to the viral genome. In Aim 1 a set of PARP14 knockdown/overexpressing cells and knockout mice will be used to determine if PARP14 restricts HSV- 1 replication in multiple cell culture models and in mice. In Aim 2 the stage of the viral lifecycle that is repressed by PARP14 will be determined using classical virological techniques, then ChIP-seq and several PARP14 truncation mutants will be utilized to define how it interacts with the viral genome. This research is innovative because PARP14 has not previously been described as an HSV-1 restriction factor. The proposed research is significant because it will provide a potential mechanism by which PARP14 restricts HSV-1 replication. Results from this study will lead to a greater understanding of how PARPs interact with DNA-containing viruses, which can ultimately lead to the rational development of novel therapies to prevent or treat HSV-1 diseases.", "keywords": [ "A549", "ADP Ribose Transferases", "Animal Model", "Binding", "Binding Proteins", "Biological Assay", "Blindness", "Cell Culture Techniques", "Cells", "ChIP-seq", "Conflict (Psychology)", "Coronavirus", "DNA", "DNA Damage", "DNA Viruses", "DNA biosynthesis", "Data", "Development", "Disease", "Double Stranded DNA Virus", "Encephalitis", "Epithelial Cells", "Face", "Funding", "Gene Expression", "Genetic Transcription", "Genome", "Genomic DNA", "Health", "Herpes Simplex Infections", "Herpesviridae", "Herpesvirus 1", "Host Defense", "Human", "Immunocompetent", "Immunocompromised Host", "Individual", "Infection", "Integration Host Factors", "KH Domain", "Knock-out", "Knockout Mice", "Life", "Life Cycle Stages", "Measures", "Mediating", "Mission", "Modeling", "Mus", "Nucleic Acids", "Outcome", "PARP9 gene", "Poly(ADP-ribose) Polymerases", "Population", "Proteins", "RNA", "Reporting", "Repression", "Research", "Role", "Sequence Analysis", "Techniques", "Testing", "United States National Institutes of Health", "Viral", "Viral Genome", "Viral Physiology", "Virus", "Virus Latency", "Virus Replication", "alveolar epithelium", "cell type", "design", "experimental study", "in vivo", "innovation", "insight", "interest", "knock-down", "lytic replication", "mutant", "novel", "novel therapeutics", "overexpression", "pathogen", "prevent", "response", "viral DNA", "virus host interaction" ], "approved": true } }, { "type": "Grant", "id": "15747", "attributes": { "award_id": "1R13CA301746-01", "title": "2025 Hormone-Dependent Cancers Gordon Research Conference and Gordon Research Seminar", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32802, "first_name": "CHRISTINA DAWN", "last_name": "GEORGE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-06", "end_date": "2026-07-31", "award_amount": 8000, "principal_investigator": { "id": 32803, "first_name": "Scott M.", "last_name": "Dehm", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2618, "ror": "", "name": "GORDON RESEARCH CONFERENCES", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "The Gordon Research Conference (GRC) and the associated Gordon Research Seminar (GRS) on “Hormone-Dependent Cancers” build on the success of five prior GRC conferences on this topic in 2013, 2015, 2017, 2019, and 2023. No meeting was held 2021 due to COVID-19 restrictions. The 2025 GRC “Hormone-Dependent Cancers: A Place in Time, from the Global to the Cellular, the Significance of Environment and Tumor Dynamics on Disease Progression” will provide the stimulating and engaging format for interaction and fruitful exchange of knowledge to allow new ideas, collaborations, and projects to develop, with the ultimate goal to decrease suffering and casualties from the disease. We will cover varied perspectives on hormone-dependent cancers through the voices of early stage and experienced investigators, as well as investigators from academia and industry. The GRS entitled “Next-Generation Approaches in Basic Science and Clinical Data Integration” will precede the GRC, and is specifically geared towards early-career scientists (ECS) including graduate students, postdoctoral fellows, and clinical fellows. Leading national and international speakers will present research that represents the entire spectrum, from basic biology to clinical application of their biological findings. The focus of the meeting is hormone-dependent cancers, with an emphasis on breast and prostate cancers, since 75% of all breast cancers and all prostate cancers are deemed hormone-dependent. The presentations will be divided among a total of 9 sessions: Keynote Session 1: Advances in Therapeutic Targeting; Session 2: Breast and Prostate Metastasis; Session 3 How Important is Location?; Session 4: Nuclear Receptors, Steroid Sisters, and Orphan Brothers; Session 5: Dynamic Actions, Epi-Genomic and Epi-Transcriptomic Plasticity with Disease Progression; Session 6: Immunology, Metabolism, and Next Generation Approaches to Targeted Treatment Strategies; Session 7: Hormone-Dependent Cancer Global and Population Outcomes; Session 8: Artificial Intelligence (AI), revolutionizing translational research; Keynote Session 2: Key Areas and Questions in Hormones & Cancer. The overall goal of the 2025 GRC/GRS is to encourage the stimulation of new projects and scientific collaborations across multiple disciplines and through informal means. With the discussion of state-of-the-art research and industry perspectives on hormone-dependent cancers, we hope to foster new discoveries, create improved therapies targeting these cancers and ultimately, improve patient outcomes.", "keywords": [ "Academia", "Address", "Area", "Artificial Intelligence", "Awareness", "Basic Science", "Biological", "Biology", "Breast", "Brothers", "COVID-19", "Clinical", "Clinical Data", "Clinical Research", "Collaborations", "Data", "Dedications", "Development", "Discipline", "Disease", "Disease Progression", "Environment", "Fostering", "Goals", "Growth", "Health Care", "Heterogeneity", "Hormones", "Hour", "Immunology", "Industry", "International", "Knowledge", "Laboratory Finding", "Location", "Malignant Breast Neoplasm", "Malignant Neoplasms", "Malignant neoplasm of prostate", "Mentors", "Mentorship", "Metabolism", "Methods", "Neoplasm Metastasis", "Nuclear Receptors", "Orphan", "Outcome", "Patient-Focused Outcomes", "Population", "Postdoctoral Fellow", "Prostate", "Publishing", "Research", "Research Personnel", "Role", "Running", "Scientist", "Senior Scientist", "Sister", "Steroids", "Students", "Time", "Translational Research", "Update", "Voice", "Work", "anti-cancer research", "career", "career development", "clinical application", "clinical development", "clinical practice", "data integration", "design", "epigenomics", "epitranscriptomics", "experience", "global health", "graduate student", "health care disparity", "improved", "innovation", "interdisciplinary collaboration", "meetings", "next generation", "novel strategies", "novel therapeutics", "patient engagement", "patient population", "peer", "posters", "skills", "success", "symposium", "targeted cancer therapy", "targeted treatment", "therapeutic target", "translational pipeline", "treatment strategy", "tumor", "tumor microenvironment" ], "approved": true } }, { "type": "Grant", "id": "15750", "attributes": { "award_id": "1R15AI191143-01A1", "title": "RNA homodimerization strand displacement pathways to extended duplexes: Atomistic details for a mechanistic paradigm to identify unique antiviral targets for current and emerging viral pandemics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32806, "first_name": "DAVID JOSEPH", "last_name": "MCDONALD", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-21", "end_date": "2028-07-31", "award_amount": 507121, "principal_investigator": { "id": 32807, "first_name": "JEFFREY D", "last_name": "EVANSECK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2621, "ror": "", "name": "DUQUESNE UNIVERSITY", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Kissing complexes (KC) and extended duplexes (ED) represent dynamic RNA structures whose interconversion is an example of strand displacement reactions that has been implicated in playing vital roles in several viruses, influencing a broad spectrum of biochemical processes including genome packaging, viral recombination, and host-pathogen interactions. However, the structural, dynamic, and energetic details on how these interconversions occur are virtually unknown yet are vital in our novel approach of identifying and characterizing previously unconsidered meta-stable pathway states to inspire future antiviral and drug resistance development. Overcoming significant challenges that hamper meaningful modelling of RNA and dimers, and associated interconversion pathways necessitate judicious choice of computational techniques and integration with experimental data across physiologically relevant timescales. Our overarching hypothesis is that by leveraging the limited kinetic and thermodynamic data reported on RNA transition pathway systems, including the human immunodeficiency virus 1 (HIV-1) dimer initiation site (DIS) and model complexes based on the bacterial E. coli DsrA-rpoS RNA-mRNA regulatory complex, a general paradigm will be developed for other known RNA dimerization systems, such as SARS-CoV, SARS-CoV-2, HCV, and future emerging RNA viruses requiring novel antiviral therapies. To address our hypothesis, we first employ a unique approach to establish the unbiased structure and dynamics of RNA structures representing both pathway endpoints of each strand displacement reaction, such as KC to ED (Aim I). Confidence in structural predictions for systems without experimental structures is engendered by comparing computations against HIV-1 DIS crystallographic structures. We next apply a minimum energy pathway technique with and without protein chaperones to identify meta-stable states (Aim II). Reliability of the method is evaluated against the kinetic and thermodynamic data reported for the KC to ED interconversion for the E. coli DsrA-rpoS RNA-mRNA regulatory complex. Finally, as a proof of concept, we will screen RNA-binding molecules and antisense oligonucleotides against identified meta-stable intermediates along the pathways (Aim III). Aligned with NIH/R15 goals, we will train undergraduates to understand the capabilities, limitations, and errors of experimental and computational chemistry to craft ultimately a seamless research approach. Our training objective is to deliver a quality research experience that motivates undergraduates to achieve their highest potential and best prepare them for scientific research and discovery. The intent is to attract and retain the nation’s diverse student talent pool, having the consequence of enriching and diversifying the U.S. workforce by adding experts in the field of biomedical chemistry. The expected scientific outcomes are to unlock novel physical insights into strand displacement reactions and provide a foundation for targeted drug design and therapeutic interventions for drug resistance of HIV-1, SARS-CoV2, and HCV viruses of current", "keywords": [ "2019-nCoV", "Address", "Anti-viral Agents", "Anti-viral Therapy", "Anti-viral resistance", "Antisense Oligonucleotides", "Bacteria sigma factor KatF protein", "Benchmarking", "Binding", "Biochemical", "Biochemical Process", "Biological", "Biophysics", "Chemistry", "Complex", "Computational Technique", "Computer software", "Computing Methodologies", "Conserved Sequence", "Coronavirus", "Crystallography", "Data", "Data Reporting", "Dimerization", "Docking", "Drug Combinations", "Drug Design", "Drug Targeting", "Drug resistance", "Elasticity", "Elements", "Escherichia coli", "Foundations", "Free Energy", "Future", "Generations", "Genetic Recombination", "Genome", "Geometry", "Goals", "HIV-1", "Health", "Hepatitis C", "Hepatitis C virus", "Homodimerization", "Immune response", "Investments", "Kinetics", "Knowledge", "Life", "Life Cycle Stages", "Messenger RNA", "Methodology", "Methods", "Modeling", "Molecular Chaperones", "Nucleocapsid", "Oligonucleotides", "Outcome", "Pathway interactions", "Pharmaceutical Preparations", "Pharmacologic Substance", "Physiological", "Play", "Process", "Proteins", "Publications", "RNA", "RNA Binding", "RNA Viruses", "RNA-targeting therapy", "Reaction", "Reporting", "Research", "Research Personnel", "Resistance", "Role", "SARS coronavirus", "Sampling", "Signal Transduction", "Site", "Small RNA", "Structure", "Students", "System", "Talents", "Techniques", "Testing", "Therapeutic Intervention", "Thermodynamics", "Training", "United States National Institutes of Health", "Validation", "Viral", "Viral Drug Resistance", "Virus", "Work", "X-Ray Crystallography", "antiviral drug development", "comparative", "computational chemistry", "dimer", "drug resistance development", "experience", "experimental study", "genomic RNA", "graduate student", "insight", "interest", "novel", "novel strategies", "pathogen", "public health relevance", "simulation", "small molecule", "student training", "trustworthiness", "undergraduate student", "viral RNA", "viral pandemic", "virtual" ], "approved": true } }, { "type": "Grant", "id": "15751", "attributes": { "award_id": "1R01AI184716-01A1", "title": "Explore a key nucleotide synthesis enzyme to develop a broad-spectrum antiviral therapy.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32808, "first_name": "MINDY I", "last_name": "DAVIS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-21", "end_date": "2030-07-31", "award_amount": 831235, "principal_investigator": { "id": 32809, "first_name": "Pinghui", "last_name": "Feng", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25475, "first_name": "Chao", "last_name": "Zhang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2622, "ror": "", "name": "UNIVERSITY OF SOUTHERN CALIFORNIA", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Title: Explore a key nucleotide synthesis enzyme to develop a broad-spectrum antiviral therapy Co-PI: Pinghui Feng (contact) and Chao Zhang With highly infectious viruses rapidly emerging and re-emerging (such as SARS-Coronavirus, influenza virus and drug-resistant herpes simplex viruses), the human society is challenged with limited options to treat diseases associated with these human viruses. In fact, antiviral therapies that effectively thwart the infection of a broad spectrum of viral pathogens are long sought in the antiviral community. In studying viral immune evasion, we have discovered that diverse viruses, including SARS- CoV-2, herpes simplex virus 1 (HSV-1) and influenza A virus (IAV), activate a key nucleotide synthesis enzyme not only to fuel nucleotide supply, but also block antiviral inflammatory cytokine production, thus efficiently promoting viral replication. We aim to target the key nucleotide synthesis enzyme for inhibition, which will deplete nucleotide supply and restore antiviral immune response to impede their replication. To achieve this goal, we have engineered conditional knockout and knockin mouse strains that will enable the genetic interrogation of the enzyme- mediated evasion of inflammatory response and metabolic reprogramming during the infection of SARS-CoV-2, IAV and HSV-1. Teaming up with a chemical biologist (Dr. Chao Zhang, University of Southern California), we have synthesized a library of small molecules and characterized specific inhibitors of the nucleotide enzyme. Furthermore, we will collaborate with a structural biologist (Dr. Santiago Ramon-Maiques, Instituto de Biomedicina de Valencia, Spain) to perform structure-activity relationship (SAR) analysis to further improve the lead small-molecule inhibitors. This study will provide a proof-of-concept to target a nucleotide synthesis enzyme in an effort to combat the infection of key human viral pathogens.", "keywords": [ "2019-nCoV", "Amino Acids", "Anti-viral Therapy", "Aspartate", "COVID-19 pandemic", "California", "Carbamoyl Transferases", "Carbamyl Phosphate", "Cell Line", "Cells", "Chemicals", "Coenzymes", "Collaborations", "Communities", "DNA Virus Infections", "DNA Viruses", "Data", "Dihydroorotase", "Disease", "Drug Kinetics", "Drug resistance", "Engineering", "Enzyme Inhibition", "Enzymes", "Gene Expression", "Genes", "Genetic", "Glutamine", "Glycoproteins", "Goals", "Herpesviridae", "Herpesvirus 1", "Homeostasis", "Host Defense", "Human", "Immune Evasion", "Immune response", "In Vitro", "Infection", "Infectious Agent", "Inflammatory", "Inflammatory Response", "Influenza A virus", "Knock-in Mouse", "Knockout Mice", "Laboratories", "Lead", "Libraries", "Ligase", "Lung", "Mediating", "Medical", "Medicine", "Metabolic", "Metabolism", "Modernization", "Mouse Strains", "Mus", "NF-kappa B", "Normal Cell", "Nucleotides", "Production", "Proliferating", "Property", "Proteins", "Pyrimidine", "RNA Viruses", "Role", "SARS coronavirus", "SARS-CoV-2 infection", "Shunt Device", "Signaling Protein", "Simplexvirus", "Societies", "Spain", "Structural Biologist", "Structure-Activity Relationship", "Tissues", "Translating", "Universities", "Viral", "Virus", "Virus Diseases", "Virus Replication", "Work", "aerobic glycolysis", "antiviral drug development", "cancer cell", "cellular targeting", "combat", "conditional knockout", "cytokine", "cytotoxicity", "deamidation", "design", "genetically modified cells", "glutamine analog", "improved", "influenzavirus", "inhibitor", "insight", "interest", "nucleotide metabolism", "pathogen", "pathogenic virus", "pharmacologic", "programs", "prototype", "recruit", "small molecule", "small molecule inhibitor", "small molecule libraries", "transcription factor" ], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1419, "count": 14184 } } }